[Jackie07]

I went to the BCA site and read some of their 'actions' from the 'Timeline' section http://bcaction.org/index.php?page=timeline:

1993 BCA testifies before the FDA in opposition to resuming the Breast Cancer Prevention Trial, a study of the drug tamoxifen in healthy women, because of reports of deaths from uterine cancer in the trial.

1995 BCA calls for the drug tamoxifen to be added to the list of substances known to the State of California to cause cancer. Despite the objections of Zeneca (the drug’s manufacturer) and then-Governor Pete Wilson, BCA’s argument prevails in 1996

1997 Citing the absence of evidence that routine mammography screening reduces breast cancer deaths for women aged 40 to 49—and noting the risks of mammography screening, including radiation exposure and the risk of false positives and false negatives—BCA publicly opposes the call by the National Cancer Institute, the American Cancer Society, and others for routine screening among women in this age group.


1997 BCA revises its mission statement and becomes the first national breast cancer organization to adopt a policy explicitly prohibiting accepting financial support from corporations, such as pharmaceutical companies and corporate polluters, that profit from or contribute to the cancer epidemic.

1999 Over the objections of other breast cancer organizations and the American Cancer Society, BCA successfully calls for the National Cancer Institute to promptly release the results of clinical trials testing high-dose chemotherapy/autologous bone marrow transplants for breast cancer.

BCA leads the call to guarantee that poor and uninsured women screened for breast cancer at state expense receive prompt access to quality treatment at state expense.

2002 BCA’s web site wins the People’s Choice Webby Award for best health web site.
BCA jointly releases the first edition of the report “State of the Evidence: What is the Connection Between the Enivronment and Breast Cancer?”

2003 BCA presents testimony to the FDA opposing attempts to reintroduce silicone breast implants, citing numerous safety concerns.
BCA launches an online aromatase inhibitor survey to collect information on the side-effects of this new form of breast cancer treatment.

2007 Asserts a unique perspective, focusing on cost and effectiveness, in opposition to approval of Avastin as a treatment for breast cancer.
Successfully argues for cancellation of STELLAR Trial, maintaining that pills for prevention always results in disease substitution.
Publishes initial Aromatase Inhibitor Side-effects Survey results

2008 Successfully advocates for removal of phthalates in cosmetics made by Secret, Arrid and Christian Dior.
Think Before You Pink Critical Questions appear in promotional literature and media statements from Susan G. Komen For The Cure and the American Cancer Society.

2009 Launches Milking Cancer campaign demanding that Eli Lilly stop making rBGH, thus removing it from the world market. Thousands take action in the fist week.
Successfully testifies on behalf of patients at the FDA against the approval of Doxil for metastatic breast cancer.
Joins ACLU in lawsuit against Myriad Genetics for their patents on breast cancer genes BRCA1 and BRCA2.
Dannon follows suit to General Mills and announces plans to go rBGH-free.
In response to consumer demand and BCA’s Think Before You Pink campaign, General Mills announces plans to go rBGH-free.

2010 BCA wins lawsuit against Myriad Genetics by challenging the company’s patents on breast cancer genes, BRCA1 and BRCA2. Patents were ruled invalid by a United States Federal judge on March 29, 2010.
Breast Cancer Action celebrates its 20th anniversary year!
FDA is responsive to BCA's concerns about ESA's, as well as time of FDA informational conference calls
Working on legislation to prohibit patenting of genes, in particular on breast cancer genes BRCA1 and BRCA2
BCA's policy is hailed as a leader in the field of screening and mammography
BCA begins exploratory conversations with Eli Lilly